Release of a new type of own branded inhalers.
Increasing market share by bringing a highly competitive product to the market.
Additional sales channel through partnerships with pharmaceutical companies.
Connection of the company's products to the PM&HM medical technology platform.
An additional image for a manufacturer of "gentle treatment" equipment using the latest digital technologies and telemedicine.
Minimum production and sales support capital expenditures (CapEx).
Production of "non-counterfeitable" inhalers for their use with "non-counterfeitable" drugs.